VITILIGO DRUGS MARKET ANALYSIS

Regional Analysis

Global Vitiligo Drug Market – Regional Analysis

On the basis of region, the global vitiligo drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to be the most lucrative region in the vitiligo drug market during the forecast period. The increasing number of R&D activities and pipeline vitiligo drug candidates are major factors propelling growth of the North America vitiligo drug market. For instance, in June 2019, phase II clinical trial conducted by Tufts Medical Center in Boston found that a topical cream - ruxolitinib, was effective in improving facial vitiligo symptomsMoreover, increasing prevalence of vitiligo in Brazilian population is expected to aid in the market growth in Latin America. For instance, according to the Pigment Cell & Melanoma Journal: 2017, out of 6,048 candidates interviewed, 97 residents reported to have vitiligo. Therefore, there is around 1.15% prevalence of vitiligo in Brazil.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa